Central role of α-synuclein oligomers in neurodegeneration in parkinson disease

Archives of Neurology

Volumn 65, Issue 12, 2008, Pages 1577-1581

  Kazantsev, Aleksey G ^a   Kolchinsky, Alexander M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Health Front Line Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER; SIRTUIN;

ARTICLE; CYTOTOXICITY; HUMAN; NERVE CELL NECROSIS; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; STRIATONIGRAL DEGENERATION;

ANIMALS; CELL DEATH; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MODELS, BIOLOGICAL; NERVE DEGENERATION; PARKINSON DISEASE;

EID: 61449084604     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.12.1577     Document Type: Article

References (17)

1. Siegel GJ, Agranoff BW, Albers RW, Fisher SK, UhlerMD. Basic Neurochemistry. Molecular, Cellular and Medical Aspects. Philadelphia, PA: Lip-pincott-Raven; 1999:922-923.
2. Pakkenberg B, Møller A, Gundersen HJ, Mourit-zen Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal sub-jects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry. 1991;54(1):30-33.
3. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature. 2000;404(6776):394-398.
4. BodnerRA, Housman DE, Kazantsev AG. New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions. Cell Cycle. 2006;5(14):1477-1480.
5. Soto C, Estrada LD. Protein misfolding and neurodegeneration. Arch Neurol. 2008;65(2):184-189.
6. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302(5646):841.
7. Galvin JE. Interaction of alpha-synuclein and dopa-mine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acfa Neuropathol. 2006;112(2):115-126.
8. Maswood N, Young J, Tilmont E, et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad SciUSA. 2004;101(52):18171-18176.
9. Guarente L. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol. 2007;72:483-488.
10. Outeiro TF, Marques O, Kazantsev A. Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta. 2008;1782(6):363-369.
11. +-dependent tubulin deacetylase. Mol Cell. 2003;11(2):437-444.
12. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39(6):889-909.
13. Yang T, Sauve AA. NAD metabolism and sirtu-ins: metabolic regulation of protein deacetyla-tion in stress and toxicity. AAPS J. 2006;8(4):E632-E643.
14. Buck SW, Gallo CM, Smith JS. Diversity in the Sir2 family of protein deacetylases. J Leukoc Biol. 2004;75(6):939-950.
15. Canelas AB, van Gulik WM, Heijnen JJ. Determination of the cytosolic free NAD/NADH ratio in Sac-charomyces cerevisiae under steady-state and highly dynamic conditions. Biotechnol Bioeng. 2008;100(4):734-743.
16. Ascherio A. Caffeinated clues from epidemiology of Parkinson's disease. Neurology. 2003;61(11)(suppl 6):S51-S54.
17. Geraets L, Moonen HJ, Wouters EF, BastA, Hage-man GJ. Caffeine metabolites are inhibitors of the nuclearenzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Biochem Pharmacol. 2006;72(7):902-910.